CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery

Author(s): Francis Robert, Sidong Huang, Jerry Pelletier*

Journal Name: Current Gene Therapy

Volume 17 , Issue 4 , 2017


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

Introduction: The ability of most laboratories to easily access CRISPR/Cas9 engineering tools has caused a revolution in biology. One of the areas that will continue to be impacted by genome editing is the drug discovery process.

Objective: CRISPR/Cas9 will not only serve to accelerate the drug discovery pipeline, but also streamline line it by identifying high-value targets, facilitating the validation of drug: target interactions and mechanisms of action, and stimulating the development of phenotype-based high throughput screens as alternatives to target-based assays.

Conclusion: We review the literature and hurdles that have been overcome to develop the current generation of tools being used to enrich the drug discovery paradigm.

Keywords: CRISPR/Cas9, Drug discovery, Target: drug interaction validation, Base editing, Druggable genome, RNA.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 4
Year: 2017
Published on: 04 January, 2018
Page: [275 - 285]
Pages: 11
DOI: 10.2174/1566523217666171121164615
Price: $65

Article Metrics

PDF: 41
HTML: 9
PRC: 3